Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550557 | 1.00 | GRIN2B (0.38) | GRIN2BGRM6LMNAGRM2MAOA | |
| SCHEMBL4638092 | 0.84 | KDM1A (0.40) | KDM1A | |
| SCHEMBL3546569 | 0.84 | HSD11B1 (0.40) | GRIN2B | |
| SCHEMBL2818160 | 0.84 | HSD11B1 (0.40) | GRIN2B | |
| SCHEMBL3556036 | 0.82 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL2817469 | 0.82 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL3547375 | 0.77 | — | — | |
| SCHEMBL2819757 | 0.77 | — | — | |
| SCHEMBL995297 | 0.76 | NPC1 (0.40) | GRIN2B | |
| SCHEMBL995296 | 0.76 | NPC1 (0.40) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7638529-B2 | anti-bacterial agents; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-08-24 | — | — | US | disclosed |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | GRIN2B 4490/4885GRM6 4789/4885LMNA 544/4885 |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, SDHB, SDHA | GRIN2B 3975/4885GRM6 4590/4885LMNA 1337/4885 |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | GRIN2B 3353/4885GRM6 4454/4885LMNA 1791/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | GRIN2B 4490/4885GRM6 4789/4885LMNA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.